Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0025-7753(02)73560-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of metformin on the level of aqueous humor inflammatory cytokines in patients with cataract.
Sci Rep
January 2025
Department of Ophthalmology, Peking University Third Hospital, Beijing, China.
This study investigated the content of inflammatory cytokines in the aqueous humor (AH) of cataract patients with type 2 diabetes (T2DM) and explored the effect of metformin on the level of cytokines. AH was collected from patients undergoing phacoemulsification and intraocular lens implantation in Peking University Third Hospital. Levels of cytokines were measured by Cytometric Bead Assay (CBA) Flex Set.
View Article and Find Full Text PDFA peptide mimic of SOCS1 modulates equine peripheral immune cells and ocular effector functions : implications for recurrent uveitis.
Front Immunol
January 2025
Microbiology and Cell Science, Institute of Food and Agricultural Science, University of Florida, Gainesville, FL, United States.
Introduction: Recurrent uveitis (RU), an autoimmune disease, is a leading cause of ocular detriment in humans and horses. Equine and human RU share many similarities including spontaneous disease and aberrant cytokine signaling. Reduced levels of SOCS1, a critical regulator of cytokine signaling, is associated with several autoimmune diseases.
View Article and Find Full Text PDFDiagnostic and Therapeutic Utility of Extracellular Vesicles in Ocular Disease.
Int J Mol Sci
January 2025
Department of Ophthalmology, Penn State University, Hershey, PA 17033, USA.
Extracellular vesicles (EVs) are lipid bilayer particles released by virtually all cells, with prominent roles in both physiological and pathological processes. The size, number, and molecular composition of released EVs correlate to the cells of origin, modulated by the cell's environment and pathologic state. The proteins, DNA, RNA, and protein cargo carried by EVs are protected by degradation, with a prominent role in targeted intercellular signaling.
View Article and Find Full Text PDFComparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis.
Int J Mol Sci
January 2025
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Shimotsuke-shi 329-0498, Tochigi, Japan.
Aflibercept and brolucizumab, two anti-VEGF agents used as intravitreal injections in ophthalmology, differ significantly in molecular weight (aflibercept-115 kDa and brolucizumab-26 kDa). Using aqueous humor samples collected after drug administration, we measured and performed a comparative analysis of pharmacokinetics and half-lives of these drugs in the human eye. Since the quantification of monoclonal antibodies (mAbs) using antigen-antibody reactions, such as ELISA, is influenced by endogenous ligands or anti-drug antibodies, we employed nano-surface and molecular-orientation limited proteolysis (nSMOL), combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS), for accurate measurements.
View Article and Find Full Text PDFThe clinical effects and mechanism of action of ranibizumab in treating myopic choroidal neovascularization.
Int Ophthalmol
January 2025
Department of Ophthalmology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, 215008, Jiangsu, China.
Purpose: Myopic choroidal neovascularization (CNV) is a common reason for visual impairment. This study investigated the clinical effects of repeated intravitreal injections of ranibizumab among patients with CNV secondary to pathologic myopia.
Methods: This study involved a single-center, non-randomized clinical prospective cohort research design including 39 patients with myopic CNV and a control group of 10 patients with cataract.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!